Gonorrhea - Pipeline Review, H2 2014

Publisher Name :
Date: 25-Oct-2014
No. of pages: 54
Inquire Before Buying

Gonorrhea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, ‘Gonorrhea - Pipeline Review, H2 2014', provides an overview of the Gonorrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gonorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gonorrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gonorrhea

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Gonorrhea and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Gonorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Gonorrhea pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Gonorrhea

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Gonorrhea pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Gonorrhea - Pipeline Review, H2 2014

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gonorrhea Overview 6
Therapeutics Development 7
Pipeline Products for Gonorrhea - Overview 7
Pipeline Products for Gonorrhea - Comparative Analysis 8
Gonorrhea - Therapeutics under Development by Companies 9
Gonorrhea - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Gonorrhea - Products under Development by Companies 12
Gonorrhea - Companies Involved in Therapeutics Development 13
Melinta Therapeutics, Inc 13
Cubist Pharmaceuticals, Inc. 14
PTC Therapeutics, Inc. 15
Genocea Biosciences, Inc. 16
Gonorrhea - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
delafloxacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
solithromycin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gonorrhea Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PTC-672 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
edodekin alfa SR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gonorrhea - Recent Pipeline Updates 35
Gonorrhea - Dormant Projects 46
Gonorrhea - Product Development Milestones 47
Featured News & Press Releases 47
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 47
Sep 06, 2014: Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin`s Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens 47
Sep 06, 2014: Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program 48
Sep 04, 2014: Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting 48
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 49
Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID 50
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Gonorrhea, H2 2014 7
Number of Products under Development for Gonorrhea - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Gonorrhea - Pipeline by Melinta Therapeutics, Inc, H2 2014 13
Gonorrhea - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 14
Gonorrhea - Pipeline by PTC Therapeutics, Inc., H2 2014 15
Gonorrhea - Pipeline by Genocea Biosciences, Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Gonorrhea Therapeutics - Recent Pipeline Updates, H2 2014 35
Gonorrhea - Dormant Projects, H2 2014 46

List of Figures
Number of Products under Development for Gonorrhea, H2 2014 7
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Target, H2 2014 18
Number of Products by Stage and Top 10 Target, H2 2014 19
Number of Products by Top 10 Mechanism of Action, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 21
Number of Products by Top 10 Route of Administration, H2 2014 22
Number of Products by Stage and Top 10 Route of Administration, H2 2014 23
Number of Products by Top 10 Molecule Type, H2 2014 24
Number of Products by Stage and Top 10 Molecule Type, H2 2014 25
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Cystic Fibrosis Report is to understand the market and pipeline status of the drugs around the Cystic Fibrosis to explore the generic development opportunities, licensing opportunitie......
  • Cysticercosis (Taeniasis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Cysticercosis (Taeniasis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Cysticercosis (Taeniasis) Report is to understand the market and pipeline status of the drugs around the Cysticercosis (Taeniasis) to explore the generic development opportu......
  • Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hypercholesterolemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hypercholesterolemia fore......
  • Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hyperparathyroidism - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hyperparathyroidism foreca......
  • Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Edema Report is to understand the market and pipeline status of the drugs around the Edema to explore the generic development opportunities, licensing opportunities and to gain competitive adva......
  • Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Hyperthyroidism - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Hyperthyroidism forecasted mar......
  • Empyema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Empyema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Empyema Report is to understand the market and pipeline status of the drugs around the Empyema to explore the generic development opportunities, licensing opportunities and to gain competitiv......
  • Enterobacteriaceae Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Enterobacteriaceae Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Enterobacteriaceae Infections Report is to understand the market and pipeline status of the drugs around the Enterobacteriaceae Infections to explore the generic develop......
  • Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Sep-2016        Price: US 4950 Onwards        Pages: 100
    Note*: This report requires 5-10 business days to complete. DelveInsight's Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Dyslipidemia forecasted market sh......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs